Landscape of Humira® biosimilars
The biosimilar market has seen a number of new biosimilars launch that reference Humira®, one of the top selling drugs in the world. Since its launch, Humira® has evolved from its original, low concentration (50mg) citrate version to a high concentration (100mg) citrate-free version. The biosimilars that have launched and are in development in reference to Humira® have differing product attributes from low concentration (50mg) vs high concentration (100mg) and citrate vs citrate free versions. Humira® biosimilars have launched with varying WAC prices, with discounts ranging from 5% up to 86%.
We believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. Our guide to biosimilars* that reference Humira® is designed to help providers and patients navigate this changing market.
Launched in the United States
| Company | Product name | Launch date | Interchangeability status | Safety Information | Concentration | Citrate free | WAC Price |
| Amgen | Amjevita™ | Dec 12, 2023 | Approved | Read more | 100MG | Yes | $1,385.22 |
| Boehringer Ingelheim | Adalimumab-adbm | October 2, 2023 | Approved | Read more | 50MG | Yes | $1,315.30 |
| Boehringer Ingelheim |
Cyltezo® | July 1, 2023 | Approved | Read more | 50MG | Yes | $6,576.49 |
| Boehringer Ingelheim | Adalimumab-adbm | May 1, 2024 | Approved | Read more | 100MG | Yes | $1,315.30 |
| Boehringer Ingelheim | Cyltezo® | May 1, 2024 | Approved | Read more | 100MG | Yes | $6,576.49 |
| Biocon |
Hulio™ |
July 1, 2023 |
Read more | 50MG | Yes |
$6,576.49 |
|
| Biocon |
Adalimumab-fkjp | July 1, 2023 |
Read more | 50MG |
Yes |
$995.00 |
|
| Celltrion |
Yuflyma | July 1, 2023 | Read more | 100MG | Yes | $6,576.50 | |
| Celltrion | Adalimumab-aaty |
May 9, 2024 | Read more | 100MG | Yes | $1,038.00 | |
| Meitheal |
Yusimry™ |
July 1, 2023 |
Read more | 50MG | Yes | $995.00 |
|
| Fresenius Kabi | Adalimumab-aacf | January 15, 2024 | Read more | 50MG | Yes | $899.00 | |
| Fresenius Kabi | Idacio® | July 1, 2023 | Read more | 50MG | Yes | $6,576.49 | |
| Optum |
Amjevita™ |
January 1, 2025 |
Approved |
Read more | 100MG |
Yes |
$1,199.00 |
| Organon | Hadlima™ | July 1, 2023 | Approved |
Read more | 50MG | No | $1,038.00 |
| Organon | Hadlima™ | July 1, 2023 | Approved |
Read more | 100MG | Yes | $1,038.00 |
| Pfizer |
Abrilada™ | November 1, 2023 | Approved |
Read more | 50MG | Yes | $6,576.49 |
| Pfizer |
Abrilada™ |
November 1, 2023 | Approved |
Read more | 50MG | Yes |
$2,769.05 |
| Sandoz | Hyrimoz™ |
July 1, 2023 |
Approved | Read more |
100MG |
Yes |
$6,576.49 |
| Sandoz |
Adalimumab-adaz |
July 1, 2023 |
Approved |
Read more |
100MG |
Yes |
$1,038.00 |
| Teva | Simlandi | May 20, 2024 | Approved | Read more | 100MG | Yes | $1,038.00 |
*WAC price represents the price for a two pack of pens or pre-filled syringes
- 1 FDA Approves Amegen's Amjevita
- 2 AMJEVITA (adalimumab-atto) injection for subcutaneous
- 4FDA Accepts Samsung Bioepis’ and Organon’s sBLA
- 5Samsung Bioepis and Organon Seek to Enter the Market
- 6PrHADLIMA®
- 7 U.S. FDA Approves Cyltezo®
- 8Boehringer Ingelheim Bpcia Strength Petition
- 9Coherus Announces U.S. FDA Approval of YUSIMRY™
- 10YUSIMRY (adalimumab-aqvh) injection
- 11Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio®
- 12HULIO® (adalimumab-fkjp) injection
- 13Sandoz receives US FDA approval for biosimilar Hyrimoz™
- 14HYRIMOZ (adalimumab-adaz) injection
- 18Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™
- 19Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab)
- 20Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
- 21 IDACIO® (adalimumab-aacf) injection
- 22 Adalimumab-adbm, Boehringer Ingelheim’s Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost
- 23 After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States
*This page is intended to assist health care providers in navigating the complicated biosimilars landscape. It should not be used to make prescribing or treatment decisions. Some therapies on this page may not have been approved by the Food and Drug Administration (FDA) or have been cleared for specific uses only. It is the responsibility of the physician to determine the FDA clearance status of each therapy in clinical practice. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.
15 FDA Approves Pfizer’s Biosimilar, ABRILADA™
16 FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™
17 ABRILADA- adalimumab-afzb
Updated: 1/22/25
Cencora.com fornisce traduzioni automatiche per facilitare la lettura del sito web in lingue diverse dall'inglese. Per queste traduzioni, sono stati fatti sforzi ragionevoli per fornire una traduzione accurata, tuttavia, nessuna traduzione automatica è perfetta né è destinata a sostituire i traduttori umani. Queste traduzioni sono fornite come servizio agli utenti di Cencora.com e sono fornite "così come sono". Non viene fornita alcuna garanzia di alcun tipo, espressa o implicita, in merito all'accuratezza, all'affidabilità o alla correttezza di una qualsiasi di queste traduzioni effettuate dall'inglese in qualsiasi altra lingua. Alcuni contenuti (come immagini, video, Flash, ecc.) potrebbero non essere tradotti in modo accurato a causa delle limitazioni del software di traduzione.
Eventuali discrepanze o differenze create nella traduzione di questo contenuto dall'inglese in un'altra lingua non sono vincolanti e non hanno alcun effetto legale per la conformità, l'applicazione o qualsiasi altro scopo. Se vengono identificati errori, ti preghiamo di contattarci. In caso di domande relative all'accuratezza delle informazioni contenute in queste traduzioni, si prega di fare riferimento alla versione inglese della pagina.
